Chong Kun Dang Pharmaceutical (185750) - Net Assets
Based on the latest financial reports, Chong Kun Dang Pharmaceutical (185750) has net assets worth ₩945.54 Billion KRW (≈ $640.78 Million USD) as of September 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (₩1.52 Trillion ≈ $1.03 Billion USD) and total liabilities (₩576.36 Billion ≈ $390.59 Million USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check 185750 asset resilience ratio to evaluate the company's liquid asset resilience ratio.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | ₩945.54 Billion |
| % of Total Assets | 62.13% |
| Annual Growth Rate | 12.3% |
| 5-Year Change | 62.51% |
| 10-Year Change | N/A |
| Growth Volatility | 8.04 |
Chong Kun Dang Pharmaceutical - Net Assets Trend (2016–2024)
This chart illustrates how Chong Kun Dang Pharmaceutical's net assets have evolved over time, based on quarterly financial data. Also explore 185750 asset base for the complete picture of this company's asset base.
Annual Net Assets for Chong Kun Dang Pharmaceutical (2016–2024)
The table below shows the annual net assets of Chong Kun Dang Pharmaceutical from 2016 to 2024. For live valuation and market cap data, see 185750 market cap.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | ₩896.38 Billion ≈ $607.46 Million |
+9.90% |
| 2023-12-31 | ₩815.64 Billion ≈ $552.74 Million |
+31.28% |
| 2022-12-31 | ₩621.29 Billion ≈ $421.04 Million |
+9.81% |
| 2021-12-31 | ₩565.81 Billion ≈ $383.44 Million |
+2.58% |
| 2020-12-31 | ₩551.59 Billion ≈ $373.81 Million |
+16.14% |
| 2019-12-31 | ₩474.95 Billion ≈ $321.87 Million |
+10.22% |
| 2018-12-31 | ₩430.90 Billion ≈ $292.01 Million |
+6.84% |
| 2017-12-31 | ₩403.29 Billion ≈ $273.31 Million |
+13.84% |
| 2016-12-31 | ₩354.25 Billion ≈ $240.07 Million |
-- |
Equity Component Analysis
This analysis shows how different components contribute to Chong Kun Dang Pharmaceutical's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 1040.2% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | ₩671.44 Billion | 75.11% |
| Other Components | ₩222.53 Billion | 24.89% |
| Total Equity | ₩893.97 Billion | 100.00% |
Chong Kun Dang Pharmaceutical Competitors by Market Cap
The table below lists competitors of Chong Kun Dang Pharmaceutical ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Anshan Senyuan Road Bridge
SHE:300210
|
$765.25 Million |
|
Guangdong Chant Group Inc
SHE:002616
|
$765.70 Million |
|
Era Co Ltd
SHE:002641
|
$766.18 Million |
|
Cementos Pacasmayo S.A.A
F:EPCC
|
$766.31 Million |
|
Shaanxi Construction Machinery Co Ltd
SHG:600984
|
$765.21 Million |
|
Renta 4 Banco S.A
MC:R4
|
$765.03 Million |
|
Sonata Software Limited
NSE:SONATSOFTW
|
$764.98 Million |
|
Guangdong Senssun Weighing Apparatus Group Ltd
SHE:002870
|
$764.96 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Chong Kun Dang Pharmaceutical's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 815,694,495,000 to 893,968,875,270, a change of 78,274,380,270 (9.6%).
- Net income of 109,072,842,040 contributed positively to equity growth.
- Dividend payments of 13,331,034,200 reduced retained earnings.
- Share repurchases of 16,007,712,760 reduced equity.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | ₩109.07 Billion | +12.2% |
| Dividends Paid | ₩13.33 Billion | -1.49% |
| Share Repurchases | ₩16.01 Billion | -1.79% |
| Other Changes | ₩-1.46 Billion | -0.16% |
| Total Change | ₩- | 9.60% |
Book Value vs Market Value Analysis
This analysis compares Chong Kun Dang Pharmaceutical's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 1.20x
- The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
- The price-to-book ratio has decreased from 2.44x to 1.20x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2017-12-31 | ₩35144.79 | ₩85700.00 | x |
| 2018-12-31 | ₩39595.07 | ₩85700.00 | x |
| 2019-12-31 | ₩43750.02 | ₩85700.00 | x |
| 2020-12-31 | ₩51018.86 | ₩85700.00 | x |
| 2021-12-31 | ₩47917.45 | ₩85700.00 | x |
| 2022-12-31 | ₩51062.05 | ₩85700.00 | x |
| 2023-12-31 | ₩64101.34 | ₩85700.00 | x |
| 2024-12-31 | ₩71134.99 | ₩85700.00 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Chong Kun Dang Pharmaceutical utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 12.20%
- The company shows good efficiency in utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 6.88%
- • Asset Turnover: 1.09x
- • Equity Multiplier: 1.63x
- Recent ROE (12.20%) is below the historical average (13.52%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2016 | 11.56% | 4.92% | 1.30x | 1.81x | ₩5.52 Billion |
| 2017 | 13.39% | 6.08% | 1.31x | 1.69x | ₩13.64 Billion |
| 2018 | 9.89% | 4.43% | 1.34x | 1.66x | ₩-473.98 Million |
| 2019 | 11.38% | 4.99% | 1.35x | 1.69x | ₩6.53 Billion |
| 2020 | 16.62% | 7.03% | 1.38x | 1.72x | ₩36.49 Billion |
| 2021 | 7.55% | 3.18% | 1.28x | 1.85x | ₩-13.88 Billion |
| 2022 | 13.01% | 5.44% | 1.32x | 1.81x | ₩18.71 Billion |
| 2023 | 26.05% | 12.73% | 1.19x | 1.72x | ₩130.95 Billion |
| 2024 | 12.20% | 6.88% | 1.09x | 1.63x | ₩19.68 Billion |
Industry Comparison
This section compares Chong Kun Dang Pharmaceutical's net assets metrics with peer companies in the Drug Manufacturers - Specialty & Generic industry.
Industry Context
- Industry: Drug Manufacturers - Specialty & Generic
- Average net assets among peers: $401,390,357,055
- Average return on equity (ROE) among peers: 0.79%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Chong Kun Dang Pharmaceutical (185750) | ₩945.54 Billion | 11.56% | 0.61x | $765.24 Million |
| Dongwha Pharm.Co.Ltd (000020) | $252.93 Billion | 10.38% | 0.28x | $113.83 Million |
| Yuhan Corp. (000100) | $407.93 Billion | 10.79% | 0.55x | $4.57 Billion |
| Yuhan Corp Preferred (000105) | $1.65 Trillion | 2.42% | 0.28x | $59.61 Million |
| Yuyu Pharma (000220) | $69.50 Billion | 3.97% | 0.28x | $46.55 Million |
| Yuyu Pharma Inc (000225) | $117.04 Billion | 1.10% | 0.32x | $17.67 Million |
| Yuyu Pharma Inc (000227) | $78.29 Billion | 7.52% | 0.42x | $42.93 Million |
| Ildong Holdings Co Ltd (000230) | $169.10 Billion | -60.53% | 4.10x | $76.14 Million |
| Samil Pharm (000520) | $127.83 Billion | 1.30% | 1.90x | $127.90 Million |
| Donga Socio Holdings (000640) | $875.86 Billion | 17.02% | 0.60x | $427.15 Million |
| Jw Pharmac (001060) | $265.44 Billion | 13.94% | 1.43x | $476.78 Million |
About Chong Kun Dang Pharmaceutical
Chong Kun Dang Pharmaceutical Corp. engages in the manufacturing, marketing, and sales of medicines in South Korea and internationally. The company provides prescription drugs for anti-hypertension, anti-hyperlipidemia, anti-diabetics, and immunosuppressants; over-the-counter medicine comprising headache remedies, dewormers, digestive aids, and vitamins; probiotics and Omega-3 supplements; and he… Read more